We're heading to the Next Gen DX Summit 2026 in DC, Aug 24–26. On Monday at 11:15 AM EDT, Dr. Lary Robinson of Moffitt Cancer Center presents on the current clinical study underway at Moffitt Cancer and the clinical potential of the CIZ1B biomarker in early lung cancer detection. buff.ly/ljgkWiL

Provider FAQ: How do licensed clinicians get set up to order CIZ1B? Providers in Dallas-Fort Worth and San Antonio, first step is account setup. Once setup is complete, physicians can access the provider portal to place orders and receive results. Review the ordering setup steps: buff.ly/W0VWQcT

San Antonio, the CIZ1B Biomarker Blood Test for Lung Cancer is now available through licensed healthcare providers. CIZ1B is designed to complement established diagnostic approaches, including LDCT, and support clinical decision-making. Patients: buff.ly/GuYec8X Clinicians: buff.ly/1zy9tqA

Dallas-Fort Worth: CIZ1B is now available through licensed healthcare providers. Patients can learn about CIZ1B and start a conversation with their healthcare provider: buff.ly/GuYec8X Clinicians can access ordering and clinical resources: buff.ly/1zy9tqA #CIZ1B #DallasHealthcare

The CIZ1B Biomarker Blood Test for Lung Cancer is designed to complement LDCT and other clinical information, not replace them. Results should be interpreted by a healthcare provider as part of a comprehensive assessment. Learn more: buff.ly/m5AToVS #CizzleBio #CIZ1B #LungCancerFAQ #PatientEducation

Primary care clinicians: CIZ1B adds biomarker data to lung cancer assessment alongside clinical judgment and appropriate imaging. Dallas and San Antonio providers can begin CIZ1B ordering setup: buff.ly/1zy9tqA #CIZ1B #PrimaryCare #LungCancer

Cizzle Bio is collaborating with BioBridge Global (BBG) to expand access to the CIZ1B Biomarker Blood Test for Lung Cancer across South Texas. The minimally invasive blood test is designed to complement LDCT screening. Read more: buff.ly/mld2Beq #CIZ1B

How does CIZ1B testing work? A licensed provider orders the test, a blood sample is collected and analyzed through a CLIA-certified laboratory, and the provider interprets the result alongside imaging, patient history, and other clinical findings. Patients: buff.ly/LnJBMtG

The CIZ1B Biomarker Blood Test for Lung Cancer does not replace LDCT. It is designed to complement imaging and other clinical information by providing an additional biomarker-based tool to support patient assessment. Learn more: buff.ly/04BfMtE #CizzleBio #CIZ1B #LDCT #LungCancerScreening

Lung cancer risk is not the same for everyone. Smoking history matters, but family history, environmental exposure, chronic lung conditions, and other factors are also important. Start a conversation with your healthcare provider: buff.ly/P2rVLbv

Healthcare providers in Dallas and San Antonio can now access clinical and ordering resources for the CIZ1B Biomarker Blood Test for Lung Cancer. Review performance information, patient considerations, specimen requirements, and ordering instructions: buff.ly/04BfMtE #CIZ1B #HealthcareProviders

CIZ1B is now commercially available to licensed healthcare providers across Dallas-Fort Worth and San Antonio following laboratory validation at OmniHealth Diagnostics. Read the announcement: buff.ly/fKAKFGK #CIZ1B #EarlyDetection

Tomorrow marks an important step forward in Cizzle Bio’s mission to support earlier lung cancer detection. More information is coming. #CizzleBio #CIZ1B #DetectEarlySaveLives

CIZ1B has completed laboratory validation at OmniHealth Diagnostics, marking an important step toward clinical availability. Cizzle Bio continues advancing CIZ1B as a minimally invasive biomarker blood test designed to support early lung cancer detection. #CizzleBio #CIZ1B

Love Your Lungs Week is a reminder that lung health also means informed conversations, better tools, and earlier answers. Cizzle Bio is advancing CIZ1B, a minimally invasive biomarker blood test designed to support lung cancer detection as an adjunct to LDCT and standard clinical assessment.

Love Your Lungs Week is a reminder to protect lung health, know your risk factors, and ask questions about early detection. At Cizzle Bio, we are advancing CIZ1B, a biomarker blood test for lung cancer coming soon to licensed U.S. healthcare providers. Protect your lungs. Know your risk.

Fact 20: Detecting cancer early is central to Cizzle Bio’s mission: Detect Early. Save Lives. As GO2 for Lung Cancer’s June 7-27 campaign closes, Cizzle Bio remains committed to awareness, education, and progress in lung cancer detection. #StepUpFor20 #LungCancerAwareness #EarlyDetection #CizzleBio

Fact 19: Early detection is central to improving outcomes and supporting more timely clinical decisions—helping clinicians and patients move forward with greater clarity. #StepUpFor20 #LungCancerAwareness #EarlyDetection #CizzleBio

Fact 18: Cizzle Bio is advancing CIZ1B, a biomarker blood test for lung cancer, coming soon to licensed U.S. healthcare providers. CIZ1B is designed to support early lung cancer detection through a minimally invasive blood draw and serve as an adjunct tool in clinical assessment. #StepUpFor20

Fact 17: Biomarker science is helping change how clinicians understand and detect cancer. Cizzle Bio is focused on advancing biomarker blood tests that support earlier detection and provide clinicians with meaningful information in patient care. #StepUpFor20 #LungCancerAwareness #EarlyDetection

Cizzle Bio will attend the AVBCC SoCal Regional Collaborative on June 26 at City of Hope. Looking forward to connecting with leaders across oncology and value-based cancer care. buff.ly/QMPuIza #Oncology #ValueBasedCare #CancerCare

Fact 16: Awareness campaigns can help people understand risk factors and start important conversations with their healthcare providers. Education can be a first step toward action. When you understand your risk, you can be better equipped to ask questions and seek guidance. #StepUpFor20

Fact 15: Lung cancer affects people across many backgrounds, including people who have never smoked. Awareness must include everyone. Lung cancer education should be clear, compassionate, and free from stigma. #StepUpFor20 #LungCancerAwareness #EarlyDetection #CizzleBio

Fact 14: Lung cancer stigma can prevent people from seeking support. Everyone impacted by lung cancer deserves compassion and care—because anyone with lungs can get lung cancer.

Fact 13: Persistent cough, shortness of breath, chest pain, coughing up blood, and unexplained weight loss are symptoms that you should discuss with your healthcare provider. Listening to your body matters. Persistent symptoms should never be ignored. #StepUpFor20 #LungCancerAwareness

Fact 12: Earlier detection can create more opportunities for timely treatment and better outcomes. This is at the heart of Cizzle Bio’s mission: helping detect cancer early, when treatment is most effective. #StepUpFor20 #LungCancerAwareness #EarlyDetection #CizzleBio

Fact 11: Lung cancer may not cause noticeable symptoms in its early stages. Because symptoms can appear later, understanding risk factors and having informed conversations with a healthcare provider are important steps in supporting earlier detection. #StepUpFor20 #LungCancerAwareness

Fact 10: Low-dose CT (LDCT) is the established screening tool for people who meet lung cancer screening criteria. Cizzle Bio is advancing CIZ1B as a biomarker blood test designed to support earlier lung cancer detection as an adjunct tool in clinical assessment.

Fact 9: The U.S. Preventive Services Task Force recommends annual lung cancer screening for adults ages 50 to 80 with a 20 pack-year smoking history who currently smoke or quit within the past 15 years.

CIZ1B has completed laboratory validation at OmniHealth Diagnostics, marking an important step toward near-term clinical availability. Cizzle Bio continues to advance biomarker science to support earlier lung cancer detection and better-informed care.